Intrathecal mesenchymal stem cell therapy in progressive multiple sclerosis: integrated blood and CSF profiling in the SMART-MS randomized trial
It is suggested that intrathecal MSC exposure in progressive MS is associated with compartmentalized CSF proteomic changes rather than broad systemic immune alterations, demonstrating the value of integrated blood–CSF profiling for dissecting treatment-associated biology in CNS-targeted interventional trials.